Evidence map›Paper›PMID 25098838›Full record

ReviewMolecular pharmaceutics2015

Synthetic biology for therapeutic applications.

Zhanar Abil, Xiong Xiong, Huimin Zhao

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Molecular pharmaceutics, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 37 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Use ofFrontiers in oncology · 2021
    Review
  11. Article
  12. Review
  13. Noise control for molecular computing.Journal of the Royal Society, Interface · 2018
    Article
  14. Genetic stability of genome-scale deoptimized RNA virus vaccine candidates under selective pressure.Proceedings of the National Academy of Sciences of the United States of America · 2017
    Article
  15. Review
  16. Synthetic Tet-inducible small hairpin RNAs targeting hTERT or Bcl-2 inhibit malignant phenotypes of bladder cancer T24 and 5637 cells.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016
    Article
  17. Synthetic biology for pharmaceutical drug discovery.Drug design, development and therapy · 2015
    Review
  18. Accelerated genome engineering through multiplexing.Wiley interdisciplinary reviews. Systems biology and medicine
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Zhanar AbilDepartment of Biochemistry, ‡Department of Chemical and Biomolecular Engineering, and §Department of Bioengineering, Department of Chemistry, Center for Biophysics and Computational Biology and Institute for Genomic Biology, University of Illinois at Urbana-Champaign , 600 South Mathews Avenue, Urbana, Illinois 61801, United States.
Xiong Xiong
Huimin Zhao
University of Illinois Urbana-Champaign · US

Funding

Structural Elucidation and Biosynthesis P01GM077596 · NIGMS · UNIVERSITY OF ILLINOIS AT URBANA-CHAMPAIGN · PI METCALF, WILLIAM W · 2007 to 2016
$15.3M
NIGMS NIH HHS GM077596NIGMS NIH HHS P01 GM077596
6 · The paper itself

Abstract

Synthetic biology is a relatively new field with the key aim of designing and constructing biological systems with novel functionalities. Today, synthetic biology devices are making their first steps in contributing new solutions to a number of biomedical challenges, such as emerging bacterial antibiotic resistance and cancer therapy. This review discusses some synthetic biology approaches and applications that were recently used in disease mechanism investigation and disease modeling, drug discovery and production, as well as vaccine development and treatment of infectious diseases, cancer, and metabolic disorders.

Indexed as

AnimalsDrug DiscoveryHumansSynthetic Biologycancer treatmentdisease mechanismdrug discoveryinfectious diseasesmetabolic disorderssynthetic biologytherapeutic treatmentvaccine development

Identifiers

PMID25098838
PMCPMC4319687
OpenAlexW2332321922

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.